MEDiC Life Sciences Partners with Hanmi Pharmaceutical
MEDiC Life Sciences has announced a groundbreaking collaboration with Hanmi Pharmaceutical aimed at advancing cancer biomarker research. This partnership promises to enhance the understanding of oncology through the application of MEDiC’s innovative MCAT™ platform.
Utilizing the MCAT™ Platform for Cancer Biomarkers
The MCAT™ platform is a sophisticated functional genomics technology that MEDiC employs to uncover potential cancer biomarkers. This platform allows the simultaneous evaluation of millions of gene-to-drug interactions, which is crucial in identifying how specific genetic mutations influence responses to cancer therapies. The collaboration focuses on determining SLS™ biomarkers, which represent a series of genetic mutations that could be particularly susceptible to specific cancer drugs.
Benefits of the Collaboration
By partnering with Hanmi Pharmaceutical, MEDiC aims to enhance the market potential of cancer treatments. The identification of multiple biomarkers will not only aid in predicting treatment responses but will also cater to a broader patient demographic. Enhanced biomarker discovery can significantly impact how effectively new cancer therapies are developed and deployed.
Strategic Investment to Fuel Growth
Under the collaboration terms, MEDiC has secured both upfront research payments and a strategic investment from Hanmi. This financial backing is expected to bolster MEDiC's research capabilities and accelerate the development of innovative cancer treatments.
Leadership Insights
Kyuho Han, Ph.D., co-founder and CEO of MEDiC, expressed enthusiasm about the partnership, stating that they look forward to advancing treatments for cancer patients with Hanmi’s clinical assets. This collaboration is seen as a significant step in exploring new avenues for oncological therapies.
Advancements in Functional Genomics
MEDiC is renowned for its pioneering approach within the realm of functional genomics. Unlike traditional methods that utilize 2D cell cultures, MEDiC employs advanced 3D tumor-like models to gain more accurate insights into cancer biology. This innovative technique is vital for identifying novel drug targets and biomarkers, which can lead to better therapeutic options for patients suffering from various solid tumors.
Partnership Opportunities
Novel therapeutic targets identified through MEDiC’s research have garnered interest from significant players in the pharmaceutical industry, including Bristol Myers Squibb and other undisclosed partners. These collaborations highlight the growing acknowledgment of MEDiC's unique technology and its potential to revolutionize cancer treatment frameworks.
About MEDiC Life Sciences
Founded in 2020, MEDiC Life Sciences is a Silicon Valley-based biotech company that focuses on discovering new therapeutic targets and biomarkers for solid tumors using its advanced MCAT™ platform. The company originated from innovative research initiated in Stanford University's SPARK program. With a strong backing from numerous undisclosed financial and strategic investors, MEDiC is poised for growth and development in delivering novel solutions to the oncology sector.
Frequently Asked Questions
What is the nature of the collaboration between MEDiC and Hanmi?
The collaboration focuses on utilizing MEDiC's MCAT™ platform to identify cancer biomarkers pertinent to Hanmi’s clinical assets.
How does the MCAT™ platform function?
MCAT™ enables simultaneous measurement of millions of interactions between cancer drugs and genetic mutations to identify effective treatment options.
What financial support has MEDiC received?
MEDiC has received upfront payments and a strategic investment from Hanmi to support their research endeavors.
What are SLS™ biomarkers?
SLS™ biomarkers represent groups of genetic mutations that may indicate patients' potential responses to specific cancer drugs, maximizing treatment effectiveness.
What is unique about MEDiC's approach to functional genomics?
MEDiC uses 3D tumor models, which enhance the accuracy and translatability of their findings compared to traditional 2D cultures, thereby improving cancer treatment research.
